Research Article

Modification of Platelet Count on the Association between Homocysteine and Blood Pressure: A Moderation Analysis in Chinese Hypertensive Patients

Jinan Zhang,1,2 Jing Li,1 Shi Chen,3 Linglin Gao,2 Xiaoluan Yan,2 Mingzhi Zhang1,1 Jia Yu,1 Fenchun Wang2, and Hao Peng1

1Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou, China
2Center for Disease Prevention and Control of Taicang City, Suzhou, China
3Department of Cardiology, Suzhou Municipal Hospital Affiliated to Nanjing Medical University, Suzhou, China

Correspondence should be addressed to Fenchun Wang; tccdcwfc@126.com and Hao Peng; penghao@suda.edu.cn

Received 4 September 2019; Revised 1 January 2020; Accepted 18 January 2020; Published 17 February 2020

Academic Editor: Kwok Leung Ong

Copyright ©2020 Jianan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Platelet consumption followed by homocysteine-induced endothelial injury suggests a crosstalk between platelet activation and homocysteine on hypertension. Platelet count has been found to modify the effect of folic acid on vascular health. However, whether platelet count could modify the contribution of homocysteine to blood pressure (BP) remains unclear. Methods. Leveraging a community-based cross-sectional survey in 30,369 Chinese hypertensive patients (mean age 62 years, 52% female), we examined the moderation of platelet count on the association between serum homocysteine and BP by constructing hierarchical multiple regression models, adjusting for conventional risk factors. If adding the interaction term of homocysteine and platelet count could explain more variance in BP and the interaction is significant, then we believe that moderation is occurring. Results. ©Q_he association between serum homocysteine and diastolic BP was significantly stronger (β = 0.092 vs. 0.035, P < 0.004) in participants with low platelet count (<210 × 10^9/L) than in those with high platelet count (≥210 × 10^9/L). Adding the interaction term of homocysteine and platelet count additionally explained 0.05% of the variance in diastolic BP (P < 0.0001), and the interaction was significant (β = −0.021, P < 0.001). Excluding participants receiving antihypertensive medications did not change our results. Conclusions. ©Q_hese results indicate that platelet count may be useful in the identification of individuals who are most beneficial to reducing-homocysteine treatments but this usefulness still needs further investigation.

1. Introduction

Essential hypertension is highly prevalent all over the world and a leading modifiable risk factor for cardiovascular disease (CVD) [1, 2]. Better understanding the underlined mechanisms of hypertension is likely to improve prevention and management of this debilitating disorder and reduce related disease burden. Homocysteine (Hcy) has been involved in the pathogenesis of hypertension by producing endothelial injury [3, 4], increasing oxidative stress [5], stimulating the proliferation of vascular smooth muscle cells (VSMCs) [6], and altering the elastic properties of the vascular wall [7]. Elevated Hcy and its related genetic variants have been associated with blood pressure [8–12], hypertension [13–15], and related vascular complications, e.g., atherosclerosis [16, 17], coronary heart disease [18, 19], and stroke [20, 21], in humans. In the process of Hcy-induced hypertension, the endothelial injury resulting from Hcy promotes platelet consumption and adherence which stimulates the proliferation of VSMCs through releasing mitogenic factors [22], thereby contributing to atherosclerosis, arterial stiffness, and high blood pressure [23, 24] Furthermore, platelet activation has been associated with Hcy [25] but also hypertension [26] in population studies. As such,
platelet response may play a potential role in enhancing the contribution of Hcy to the risk and severity of hypertension. In support of this hypothesis, a recent trial found that platelet count interacted with Hcy and modified the effect of folic acid on risk of stroke [27]. To date, however, the moderation or interaction between Hcy and platelet count on blood pressure has been poorly studied but deciphering their crosstalk is likely to provide novel insights into mechanisms of hypertension and may also identify novel therapeutic targets for this debilitating disorder and related conditions. The aim of this study was to examine the moderation and interaction of platelet count on the association between homocysteine and blood pressure in more than 30 thousand Chinese adults with essential hypertension.

2. Methods

2.1. Participants. Hyperhomocysteinemia (HHcy) has been considered extremely and highly prevalent in Chinese population in the last decades due to lack of mandatory folic acid fortification of grain products, insufficient consumption of folate-containing foods, a low rate of folic acid supplementation, and a high prevalence of the methyl-
enetetrahydrofolate reductase (MTHFR) C677T gene mutation (25% in Chinese vs. 10% to 12% in the general U.S. population) [28]. After decades of efforts, e.g., health education and dietary promotion, the prevalence of HHcy is supposed to be declined in this population, hypertensive patients in particular. To estimate the prevalence of HHcy among Chinese hypertensive patients, we conducted a community-based cross-sectional survey in 21 communities residing in Taicang, a traditional but economically developed county in China. There is an effective system of registry and management of chronic diseases, including hypertension, diabetes, and CVD, covering all of the adult residents in this county. More than 70,000 living hypertensive patients were registered in this system by the end of 2016. Of them, 30,379 patients agreed to participate in our cross-sectional clinical examination operated in 2017 and gave written informed consent. After excluding participants with missing data on either serum Hcy or platelet count (N = 100), a total of 30,369 hypertensive patients were finally included in the current analysis. Hypertension defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg or use of antihypertensive medications in the last 2 weeks was used in our study [29].

2.2. Assessment of Homocysteine. Overnight fasting venous blood samples were collected for each participant and shipped to the core laboratory of the Center for Disease Prevention and Control of Taicang within four hours after venipuncture. All laboratory tests were performed at this laboratory on the same day. Serum total Hcy was determined by chemistry enzymatic assay (Axis-Shield Diagnostics Ltd., Dundee, UK) on the Cobas c501 analyzer (Roche Diagnostics, Indianapolis, IN). The intra- and interassay coefficients of variation were less than 7.5% and 4.5%, respectively.

2.3. Measurement of Blood Pressure. Blood pressure was measured three times by trained staff using a standard mercury sphygmomanometer and a cuff of appropriate size according to a standard protocol [29], after the participants had been resting for at least 5 min in a relaxed, sitting position. The first and fifth Korotkoff sounds were recorded as systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively. The mean of the three measurements was used in statistical analyses.

2.4. Measurement of Other Risk Factors. Blood cell analysis, including platelet count, plateletcrit, platelet distribution width, and mean platelet volume, was obtained using a BC-3200 hematology analyzer (Mindray Medical, Shenzhen, China). Fasting glucose, blood lipids including total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), and creatinine were measured by standard laboratory methods [30]. Diabetes was defined as fasting glucose over 7.0 mmol/L and/or receiving hypoglycemic medications in the last 2 weeks [31]. Body weight (kg) and height (cm) were measured when participants wore light clothes and no shoes by trained staff. Body mass index (BMI) was calculated by dividing weight in kilograms by the square of height in meters (kg/m²).

2.5. Statistical Analysis. Given the extreme sample of only hypertensive patients included in our study, z-transformation was applied to standardize the distribution of SBP and DBP with a mean of 0 and a standard deviation of 1. The generated z-scores were used in all downstream analyses. To examine whether platelet count modifies the association between Hcy and blood pressure, we first constructed a robust linear regression model in which z-transformed SBP/DBP was the dependent variable and log-transformed Hcy (log-Hcy) was the independent variable, adjusting for age, sex, receiving antihypertensive medication (y/n), fasting glucose, LDL-C, HDL-C, and creatinine in participants with low and high platelet count (less than vs. over 210 × 10⁹/L), due to that platelet count less than 210 × 10⁹/L has been identified to modify the efficacy of folic acid in preventing stroke in Chinese hypertensive patients [27]. The robust regression model was used here to account for the influence of extreme values on the model fitting. The modification of platelet count levels on the association between Hcy and blood pressure was tested by comparing the regression coefficients of the linear models fitted in participants with low vs. high platelet count. To further examine whether and to what extent does platelet count moderate the association between Hcy and blood pressure, we constructed the following hierarchical multiple regression models:

(i) Model 1: the regression of blood pressure on log-Hcy and platelet count, adjusting for covariates listed above

(ii) Model 2: add the interaction term of log-Hcy × platelet count as a predictor to model 1
To facilitate comparison, all variables were centered to a distribution with a mean of 0 and a standard variation of 1. If the $R^2$ of Model 2 is significantly improved compared with Model 1 and the interaction effect is significant, then we believe that moderation is occurring. Moderation analysis was performed using R package “medmod” [32].

2.6. Sensitivity Analysis. To examine whether medications affect our results, we repeated the analysis after excluding participants receiving antihypertensive or antidiabetic medications. We additionally examined the moderation of other markers of platelet consumption including plateletcrit, platelet distribution width, and mean platelet volume on the association between Hcy and blood pressure. All statistical analyses were conducted using SAS statistical software (version 9.4; Cary, North Carolina, USA) unless otherwise noted. A two-tailed $P$ value of less than 0.05 was considered statistically significant.

3. Results

This study included 30,369 hypertensive patients (mean age 62 years, 52% female) including 4,160 (14%) patients not receiving antihypertensive drugs. Among these, 61%, 43%, and 22% individuals suffered HHcy defined as a serum Hcy level over 10, 12, and 15 $\mu$mol/L, respectively. Table 1 presents the clinical characteristics of these hypertensive patients according to platelet count. Participants with low platelet count were more likely to be elder, male, and have lower levels of SBP, DBP, BMI, blood lipids, and serum Hcy, but a higher level of creatinine than those with high platelet count (all $P<0.001$). Higher levels of platelet consumption as indicated by higher MPV and PDW and lower PCT occurred in participants with low platelet count compared with those with high platelet count (all $P<0.05$).

3.1. Association between Hcy and Blood Pressure according to Platelet Count. Table 2 shows the associations of serum Hcy with SBP and DBP in hypertensive patients with low $vs.$ high platelet count, independent of age, sex, BMI, fasting glucose, lipids, kidney function, and antihypertensive medication. In participants with low platelet count, higher serum Hcy was significantly associated with higher SBP (bottom-line significant with $\beta=0.026$, $P=0.079$) and DBP ($\beta=0.092$, $P<0.001$), whereas these associations were not significant in participants with high platelet count. And the magnitudes of the associations of serum Hcy with SBP ($P=0.017$) and DBP ($P=0.004$) in hypertensive patients with low platelet count were much stronger than that in those with high platelet count. These results indicated a possible modification of platelet count on the association between serum Hcy and blood pressure.

3.2. Moderation of Platelet Count on the Association between Hcy and Blood Pressure. The results of moderation analysis further demonstrated the modification of platelet count on the association between Hcy and DBP. As shown in Table 3, after further adjusting for the interaction term of Hcy and platelet count, the magnitude of the association between serum Hcy and DBP remained unchanged and significant but the $R^2$ of the regression model significantly increased by 0.0005 ($P=0.0001$). Furthermore, the interaction between Hcy and platelet count was significantly associated with DBP ($\beta=-0.021$, $P<0.001$). These results indicated that the association between Hcy and DBP may be partially moderated by platelet count and seemed to be stronger in participants with low platelet count. We failed to identify statistically but bottom-line significant moderation of platelet count on the association between Hcy and SBP ($\beta=-0.011$, $P=0.057$).

3.3. Results of Sensitivity Analysis. After excluding participants receiving antihypertensive drugs ($N=26,209$), the association between Hcy and blood pressure was significant in patients with low platelet count but not significantly stronger than that in patients with high platelet count (Supplementary Table S1). Although we failed to observe a statistically significant moderation of platelet count on the association between Hcy and blood pressure in this small subsample of hypertensive patients, the inconsistent results in patients with low $vs.$ high platelet count may support our findings in total participants. Excluding participants receiving antidiabetic medications did not change our results (Supplementary Table S2). In addition to platelet count, plateletcrit also significantly moderated the association between Hcy and blood pressure (all $P<0.05$, Supplementary Table S3). We did not find significant moderation of platelet distribution width or volume on the association between Hcy and blood pressure (Supplementary Tables S4 and S5).

4. Discussion

A recent clinical trial including 10,789 Chinese hypertensive adults found that platelet count modified the effect of folic acid supplementation on the risk of incident stroke [27]. This secondary analysis of China Stroke Primary Prevention Trial (CSPPT) introduced for the first time a probable moderating effect of platelet count on the contribution of Hcy to risks of stroke and other vascular disorders, such as hypertension, but it may be prone to uncover a false-positive finding. In order to replicate this finding of interest, our study examined the moderation of platelet count on the association between Hcy and blood pressure, leveraging a large sample of hypertensive patients with available data on Hcy. The results showed that the association between Hcy and blood pressure, DBP in particular, was partially moderated by platelet count and was significantly stronger in participants with low platelet count than that in those with high platelet count, regardless of antihypertensive medications and metabolic risk factors. Platelet consumption may be involved in the progression of hypertension through mechanisms beyond metabolic risk factors.

In line with our study, the identified association between Hcy and blood pressure was also demonstrated by many previous studies. For example, basic experiments found that injection of Hcy resulted in blood pressure elevation in rats.
Table 1: Clinical characteristics of study participants according to platelet count.

| Characteristics                        | Low platelet count (<210 × 10^9/L) | High platelet count (≥210 × 10^9/L) | P      |
|----------------------------------------|-----------------------------------|------------------------------------|--------|
| No. of participants                   | 21,980                            | 8,389                              | <0.001 |
| Age (years)                           | 63.3 ± 7.1                        | 61.7 ± 7.2                         |        |
| Sex, men (%)                          | 11,087 (50.44)                    | 3,516 (41.91)                      | <0.001 |
| Antihypertensive medication, n (%)    | 18,897 (85.97)                    | 7,312 (87.16)                      | 0.007  |
| Body mass index (kg/m^2)              | 24.71 ± 3.36                      | 25.08 ± 3.31                       | <0.001 |
| Fasting glucose (mmol/L)              | 5.92 ± 1.48                       | 5.94 ± 1.46                        | 0.252  |
| Total cholesterol (mmol/L)            | 4.82 ± 1.01                       | 5.10 ± 1.04                        | <0.001 |
| Triglycerides (mmol/L)                | 1.80 ± 1.40                       | 1.96 ± 1.43                        | <0.001 |
| LDL-C (mmol/L)                        | 2.78 ± 0.81                       | 3.06 ± 0.84                        | <0.001 |
| HDL-C (mmol/L)                        | 1.49 ± 0.48                       | 1.47 ± 0.45                        | <0.001 |
| Creatinine (mmol/L)                   | 73.37 ± 36.96                     | 69.57 ± 30.47                      | <0.001 |
| Systolic blood pressure (mmHg)        | 143.8 ± 17.6                      | 144.6 ± 17.5                       | <0.001 |
| Diastolic blood pressure (mmHg)       | 83.0 ± 10.5                       | 84.0 ± 10.7                        | <0.001 |
| Log-Hcy                                | 2.40 ± 0.49                       | 2.41 ± 0.48                        | 0.037  |

All results are expressed in mean ± SD unless otherwise noted. LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; Log-Hcy: log-transformed homocysteine.

Table 2: The association between serum homocysteine and blood pressure according to platelet count.

| Subgroups                        | z-transformed SBP | z-transformed DBP |
|----------------------------------|-------------------|------------------|
|                                  | β* (SE)           | P*               | β† (SE) | P†  |
| Total participants               | 0.017 (0.013)     | 0.181            | 0.078 (0.012) | <0.001 |
| Subgroup by quartiles of platelet count |                    |                  |         |      |
| Q1 (<146 × 10^9/L)              | -0.010 (0.025)    | 0.683            | 0.108 (0.024) | <0.001 |
| Q2 (146–178 × 10^9/L)           | 0.053 (0.026)     | 0.044            | 0.098 (0.025) | <0.001 |
| Q3 (179–213 × 10^9/L)           | 0.044 (0.026)     | 0.091            | 0.058 (0.025) | 0.019  |
| Q4 (≥214 × 10^9/L)              | -0.027 (0.026)    | 0.297            | 0.039 (0.025) | 0.119  |
| Subgroup by platelet count referring to CSPPT |                    |                  |         |      |
| Platelet count <210 × 10^9/L    | 0.026 (0.015)     | 0.079            | 0.092 (0.014) | <0.001 |
| Platelet count ≥210 × 10^9/L    | -0.017 (0.025)    | 0.502            | 0.035 (0.024) | 0.144  |

* The increase of z-transformed SBP (β) per unit increment of log-transformed homocysteine and its significance test (P); † the increase of z-transformed DBP (β) per unit increment of log-transformed homocysteine and its significance test (P); ‡ the significance test of the difference in the regression coefficients between the two subgroups.

Table 3: Moderation of platelet count on the association between serum homocysteine and blood pressure.

| Independent variables                        | Model 1 | Model 2 |
|-----------------------------------------------|---------|---------|
| Model 1                                       |         |         |
| z-transformed SBP                             | β (SE)  | P       | R^2    | β (SE)  | P       | R^2    |
| z-transformed log-Hcy                         | 0.007 (0.006) | 0.240 | 0.0478 | 0.007 (0.006) | 0.271 |
| z-transformed platelet count                  | 0.017 (0.006) | 0.004 | 0.005  | 0.0479 |
| Interaction term                              | —       | —       | —      | —       |         |        |
| Moderation tests                              |         |         |
| z-transformed SBP                             |         |         |
| z-transformed log-Hcy                         | 0.036 (0.006) | <0.001 | 0.0975 | 0.035 (0.006) | <0.001 |
| z-transformed platelet count                  | 0.019 (0.006) | 0.001  | 0.001  | 0.0980 |
| Interaction term                              | —       | —       | —      | —       |         |        |

Log-Hcy: log-transformed homocysteine; model 1: the regression of blood pressure on z-transformed log-Hcy and z-transformed platelet count, adjusting for age, sex, body mass index, fasting glucose, lipids, and creatinine; model 2: further adjusting for the interaction term of z-transformed log-Hcy and z-transformed platelet count.
[33]. Genome-wide association studies revealed that several variants in the MTHFR, a gene regulating Hcy synthesis [34], were associated with blood pressure in humans, regardless of hypertensive status and antihypertensive medications [8, 9, 35]. The positive association between circulating Hcy and blood pressure has also been found in diverse populations by many large-scale epidemiological studies [36], including the Third National Health and Nutrition Examination Survey (NHANES) [37]. The association between Hcy and blood pressure has been mostly studied in general populations comprising normal and hypertensive individuals, and the role of Hcy in the progression of hypertension is not well studied. Our study included only hypertensive individuals and found a significant association between Hcy and blood pressure in this population and therefore may provide an initial evidence for the contributing role of Hcy in the progression of hypertension.

In addition to the association between Hcy and blood pressure, the other important goal of our study is to examine the moderation effect of platelet count on this association. In line with the results from the CSPPT [27], we found that the association between Hcy and blood pressure was significantly moderated by platelet count, where this association was significantly stronger for participants with low platelet count. Although the underlined mechanisms are not clear, some probable mechanisms shared by Hcy and platelet involved in vascular health may explain, at least partly, the moderating effect of platelet count on the association between Hcy and blood pressure. As an illustration, as a fundamental pathogenesis of hypertension, endothelial dysfunction could be resulted by Hcy [38] and can stimulate aggregation and adherence of platelet [39]. Platelet consumption and activation consequently stimulate the proliferation of VSMCs by releasing mitogenic factors [22]. Further, Hcy per se could also induce the proliferation of VSMCs 6 probably through interaction with platelet, indicated by an Hcy-dependent expression of the platelet-derived growth factor [40], thereby contributing to atherosclerosis, arterial stiffness, and high blood pressure [23, 24]. Together with these basic studies, our findings may suggest that the contribution of Hcy to atherosclerosis and the progression of hypertension may be boosted in individuals with a status of high active platelet consumption. In further support of this speculation, we found that higher Hcy (after log-transformation) was significantly associated with higher levels of platelet count (β = 1.28, \(P = 0.045\)), mean platelet volume (β = 0.059, \(P = 0.005\)), and plateletcrit (β = 0.002, \(P = 0.002\)) and a lower level of platelet distribution width (β = −0.029, \(P = 0.013\)) in our study. We also found that plateletcrit, a complementary analysis of platelet count and measures the percentage of platelets in the blood [41], significantly moderated the association between Hcy and blood pressure in our study. The more active is platelet consumed, the fewer platelets are in the circulation. Although we failed to identify a statistically significant moderation for the other two markers of platelet consumption activation, platelet distribution width and mean platelet volume [42, 43], the identified statistically significant moderation of platelet count and plateletcrit on the association between Hcy and blood pressure, together with prior consistent findings, may shed light on a biological moderation effect of platelet consumption on modifying vascular toxicity of Hcy. The vascular toxicity of Hcy, indicated by a higher blood pressure here, seems relatively greater in individuals who do not have reduced platelet production. Of note, we found that the magnitude of the association between Hcy and DBP seemed higher than that between Hcy and SBP. This phenomenon is also observed in prior population studies [44]. Although some mechanisms through which Hcy leads to DBP dysfunction have been indicated, e.g., reduced the production of vasodilators such as endogenous nitric oxide [45], reduced arterial wall compliance through impairing vascular matrix metalloproteinase activity [46], and increased endothelial-myocyte uncoupling [47], the mechanisms underlining this interesting phenomenon are still not very clear and warranted further investigation because DBP was considered associated with blood flow in the brain.

This study reserves the first to examine the moderation of platelet count on the association between Hcy and blood pressure in populations. The strengths of our study included the large sample size, comprehensive assessment, and adjustment for multiple confounding factors including metabolic factors, stratification analysis by using antihypertensive medications to eliminate its bias, and the careful moderation analysis by constructing hierarchical multiple regression models. Some limitations of our study also should be acknowledged. First, the cross-sectional study design prevents us from exploring the causal or temporal relationship between Hcy, platelet count, and blood pressure elevation. Second, only Chinese hypertensive adults were included in our study. Given the higher prevalence of HHcy in Chinese than European ancestry populations [28], the generalizability of our findings to other ethnic groups, nonhypertensive adults, or younger populations is concerned. Third, to facilitate data interpretation, we used the same cutoff value of platelet count as used in the CSPPT [27]. In fact, it is still unclear about the reference level of platelet count that could be used in clinical settings to identify individuals who are sensitive to Hcy or folic acid supplementation. However, our study may suggest that platelet count possesses a potential to identify individuals who are the most appropriate for the treatment of folic acid or vitamin B12. Fourth, we did not obtain data on organ damage of hypertension, e.g., CVD events and chronic kidney disease, although serum creatinine was adjusted for in our statistical analysis. Whether and to what extent these organic dysfunctions influence our results is not clear. Fifth, although blood pressure was measured three times, the level of blood pressure under analysis was obtained on only 1 occasion. Inaccuracy may still exist and may affect our data interpretation. Sixth, we did not obtain data on the use of B12 or folate supplements which directly influence Hcy levels.
Data Availability

All information analyzed is deidentified, and the anonymous data will be shared by a request to the corresponding author at penghao@suda.edu.cn.

Additional Points

Perspectives. The moderation effect of platelet count on the contribution of Hcy to vascular disorders suggested by the CSPPT [27] was successfully demonstrated by our study in a large sample of Chinese hypertensive adults. The association between serum Hcy and blood pressure was significantly stronger in participants with low vs. high platelet count and was partially moderated by platelet count. These results indicate that platelet count may be useful in the identification of individuals who are most beneficial to reducing-homocysteine treatments but this potential usefulness still needs further investigation.

Disclosure

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jianan Zhang, Jing Li, and Shi Chen contributed equally to this work and should be considered as co-first authors.

Acknowledgments

We are deeply appreciative of the participants in this study and thank all staff for their support and assistance. Especially, we thank the Center for Disease Prevention and Control of Taicang City for their support in the recruitment of participants. This study was supported by the National Natural Science Foundation of China (nos. 81872690, 81673263, and 81320108026) and a project of the Priority Academic Program Development of Jiangsu Higher Education Institutions, China.

Supplementary Materials

To further examine the robustness of our results, we performed a series of sensitivity analyses. Specifically, to examine whether antihypertensive medications affect our results, we repeated the analyses in participants receiving antihypertensive medications or not. As shown in Supplementary Table S2, excluding participants receiving antihypertensive medications did not change our results. The association between Hcy and blood pressure was significantly stronger in participants with low platelet counts. To examine whether other index of platelet consumption could modify the association between Hcy and blood pressure, we additionally examined the association between Hcy and blood pressure in subgroups by plateletcrit (Supplementary Table S3), platelet distribution width (Supplementary Table S4), and mean platelet volume (Supplementary Table S5). We found that plateletcrit also significantly moderated the association between Hcy and blood pressure (all \( P < 0.05 \)). We did not find significant moderation of platelet distribution width or volume on the association between Hcy and blood pressure. (Supplementary Materials)

References

[1] A. M. Sarki, C. U. Nduka, S. Stranges, N.-B. Kandala, and O. A. Uhman, “Prevalence of hypertension in low- and middle-income countries,” Medicine, vol. 94, no. 50, p. e1959, 2015.

[2] L. A. Fleisher, K. E. Fleischmann, A. D. Auerbach et al., “2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines,” Circulation, vol. 130, no. 24, pp. 278–333, 2014.

[3] S. Pushpakumar, S. Kundu, and U. Sen, “Endothelial dysfunction: the link between homocysteine and hydrogen sulfide,” Current Medicinal Chemistry, vol. 21, no. 32, pp. 3662–3672, 2014.

[4] L. A. Harker, S. J. Slichter, C. R. Scott, and R. Ross, “Homocystinemia,” New England Journal of Medicine, vol. 291, no. 11, pp. 537–543, 1974.

[5] Z. P. You, Y. Z. Zhang, Y. L. Zhang, L. Shi, and K. Shi, “Homocysteine induces oxidative stress to damage trabecular meshwork cells,” Experimental & Therapeutic Medicine, vol. 15, pp. 4379–4385, 2018.

[6] S. C. Ma, H. P. Zhang, Y. Jiao et al., “Homocysteine-induced proliferation of vascular smooth muscle cells occurs via pten hypermethylation and is mitigated by resveratrol,” Molecular Medicine Reports, vol. 17, no. 4, pp. 5312–5319, 2018.

[7] M. Sharorgorsky, M. Boaz, S. Pasternak et al., “Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: which of them is really important in atherogenesis?” Diabetes/Metabolism Research and Reviews, vol. 25, no. 1, pp. 70–75, 2009.

[8] L. V. Wain, G. C. Verwoert, P. F. O’Reilly et al., “Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure,” Nature Genetics, vol. 43, no. 10, pp. 1005–1011, 2011.

[9] L. V. Wain, A. Vaez, R. Jansen et al., “Novel blood pressure loci and gene discovery using genome-wide association study and expression data sets from blood and the kidney,” Hypertension, vol. 70, no. 3, 2017.
[10] J. C. Xie, Y. Y. Lin, X. H. Liu et al., "Homocysteine is associated with exaggerated morning blood pressure surge in patients with acute ischemic stroke," *Journal of Stroke & Cerebrovascular Diseases*, vol. 27, no. 10, pp. 2650–2656, 2018.

[11] H. Wu, B. Wang, Q. Ban et al., "Association of total homocysteine with blood pressure in a general population of Chinese adults: a cross-sectional study in Jiangsu province, China," *BMJ Open*, vol. 8, no. 6, Article ID e021103, 2018.

[12] M. Momin, F. Fan, J. Li et al., "Associations of plasma homocysteine levels with peripheral systolic blood pressure and noninvasive central systolic blood pressure in a community-based Chinese population," *Scientific Reports*, vol. 7, no. 1, p. 6316, 2017.

[13] Y.-L. Wu, C.-Y. Hu, S.-S. Lu et al., "Association between homocysteine as a risk factor in early and mid-stage atherosclerosis," *Circulation*, vol. 106, no. 22, pp. 2800–2805, 2002.

[14] X. Kong, X. Huang, M. Zhao et al., "Platelet count affects efficacy of folic acid in preventing first stroke," *Journal of the American College of Cardiology*, vol. 71, no. 19, pp. 2136–2146, 2018.

[15] S. Jiang, J. Li, Y. Zhang et al., "Methylenetetrahydrofolate reductase c677t polymorphism, hypertension and risk of stroke: a prospective, nested case-control study," *International Journal of Neuroscience*, vol. 127, no. 3, pp. 253–260, 2017.

[16] A. V. Chobanian, G. L. Bakris, H. R. Black et al., "The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure the JNC 7 report," *JAMA*, vol. 289, no. 19, pp. 2560–2572, 2003.

[17] H. Peng, Q. Zhang, X. Cai et al., "Association between high serum soluble corin and hypertension: a cross-sectional study in a general population of China," *American Journal of Hypertension*, vol. 28, no. 9, pp. 1141–1149, 2015.

[18] American Diabetes Association, "Diagnosis and classification of diabetes mellitus," *Diabetes Care*, vol. 33, no. Suppl 1, pp. S62–S69, 2010.

[19] R. Selker, "Medmod: simple mediation and moderation analysis," 2017, https://CRAN.R-project.org/package=medmod.

[20] Y. Chen, H. Zhang, E. Liu, C. B. Xu, and Y. Zhang, "Homocysteine regulates endothelin type b receptors in vascular smooth muscle cells," *Vascular Pharmacology*, vol. 87, pp. 100–109, 2016.

[21] J. B. van Meurs, G. Pare, S. M. Schwartz et al., "Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease," *The American Journal of Clinical Nutrition*, vol. 98, no. 3, pp. 668–676, 2013.

[22] C. Newton-Cheh, T. Johnson, V. Gateva et al., "Genome-wide association study identifies eight loci associated with blood pressure," *Nature Genetics*, vol. 41, no. 6, pp. 666–676, 2009.

[23] C. van Guldener, P. W. B. Nanayakkara, and C. D. A. Stehouwer, "Homocysteine and blood pressure," *Current Hypertension Reports*, vol. 5, no. 1, pp. 107–113, 2003.

[24] U. Lim and P. A. Cassano, "Homocysteine and blood pressure in the third national health and nutrition examination survey, 1988–1994," *American Journal of Epidemiology*, vol. 156, no. 12, pp. 1105–1113, 2002.

[25] J. Zhu, Y. Zhao, L. Yu, M. Wang, Q. Li, and S. Xu, "Pioglitazone restores the homocysteineimpaired function of endothelial progenitor cells via the inhibition of the protein kinase c/NADPH oxidase pathway," *Molecular Medicine Reports*, vol. 18, pp. 1637–1643, 2018.

[26] M. Shechter, A. Shechter, H. Hod et al., "Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction," *Platelets*, vol. 23, no. 3, pp. 202–210, 2012.

[27] X. B. Han, H. P. Zhang, C. J. Cao et al., "Aberrant DNA methylation of the PDGF gene in homocysteine-mediated vsmc proliferation and its underlying mechanism," *Molecular Medicine Reports*, vol. 10, no. 2, pp. 947–954, 2014.
[41] I. Akpinar, M. R. Sayin, Y. C. Gursoy et al., “Plateletcrit. A platelet marker associated with saphenous vein graft disease,” 
*Herz*, vol. 39, no. 1, pp. 142–148, 2014.

[42] J. C. Arevalo-Lorido, J. Carretero-Gómez, A. Álvarez-Oliva, C. Gutiérrez-Montaño, J. M. Fernández-Recio, and F. Najarro-Díez, “Mean platelet volume in acute phase of ischemic stroke, as predictor of mortality and functional outcome after 1 year,” *Journal of Stroke & Cerebrovascular Diseases*, vol. 22, no. 4, pp. 297–303, 2013.

[43] L. I. Yue, “Evaluation on platelet distribution width as a novel specific marker of platelet activation,” *Journal of Chongqing Medical University*, vol. 36, pp. 200–202, 2011, in Chinese.

[44] R. Dinavahi, N. Cossrow, H. Kushner, and B. Falkner, “Plasma homocysteine concentration and blood pressure in young adult African Americans,” *American Journal of Hypertension*, vol. 16, no. 9, pp. 767–770, 2003.

[45] N. Toda and T. Okamura, “Hyperhomocysteinemia impairs regional blood flow: involvements of endothelial and neuronal nitric oxide,” *Pflügers Archiv—European Journal of Physiology*, vol. 468, no. 9, pp. 1517–1525, 2016.

[46] M. M. Steed and S. C. Tyagi, “Mechanisms of cardiovascular remodeling in hyperhomocysteinemia,” *Antioxidants and Redox Signaling*, vol. 15, no. 7, pp. 1927–1943, 2011.

[47] N. Tyagi, K. S. Moshal, D. Lominadze, A. V. Ovechkin, and S. C. Tyagi, “Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip goldblatt hypertension mouse model,” *Canadian Journal of Physiology and Pharmacology*, vol. 83, no. 7, pp. 583–594, 2005.